Department of Research, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven.
Ann Oncol. 2014 Jan;25(1):64-8. doi: 10.1093/annonc/mdt424. Epub 2013 Nov 7.
Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors.
Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years.
For stage I, conditional 5-year relative survival remained ~95% up to 15 years after diagnosis (a stable 5-year excess mortality rate of 5%). For stage II, excess mortality remained 10% for those aged 15-44 or 45-59 and 15% for those aged 60-74. For stage III, excess mortality decreased from 35% at diagnosis to 10% at 15 years for those aged 15-44 or 45-59, and from ~40% to 30% for those aged ≥60.
Patients with stage I or II breast cancer had a (very) good long-term prognosis, albeit exhibiting a small but significant excess mortality at least up to 15 years after diagnosis. Improvements albeit from a lower level were mainly seen for patients who had been diagnosed with stage III disease. Caregivers can use this information to better inform (especially disease-free) cancer survivors about their actual prognosis.
随着 I-III 期乳腺癌患者的预后相对较好且不断改善，可能会出现晚期复发、新原发肿瘤和治疗的晚期副作用。我们深入了解了长期乳腺癌幸存者的预后。
所有年龄在 15-89 岁之间、1989-2008 年间被诊断为 I-III 期乳腺癌的 205827 名女性患者的数据均来自荷兰癌症登记处。对每例患者，从诊断后开始计算随后每一年的 5 年条件相对生存率，随访时间长达 15 年。
对于 I 期患者，在诊断后 15 年内，5 年条件相对生存率保持在约 95%（稳定的 5 年超额死亡率为 5%）。对于 II 期患者，15-44 岁或 45-59 岁患者的超额死亡率为 10%，60-74 岁患者的超额死亡率为 15%。对于 III 期患者，从诊断时的 35%降至 15-44 岁或 45-59 岁患者的 10%，从约 40%降至≥60 岁患者的 30%。
I 期或 II 期乳腺癌患者的长期预后（非常）良好，尽管在诊断后至少 15 年内仍存在小但显著的超额死亡率。III 期患者的预后有所改善，尽管从较低水平开始。护理人员可以使用这些信息，更好地告知（尤其是无疾病）癌症幸存者他们的实际预后。
